Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.45 |
| ▸ | GABRD | O14764 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.45 |
| ▸ | GABRE | P78334 | 1/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28445014 | 0.87 | NR4A2 (0.52) | NR4A2MAPTGPR84CREBBPPOLB | |
| SCHEMBL7497428 | 0.83 | NR4A2 (0.52) | NR4A2MAPTGPR84CREBBPPOLB | |
| SCHEMBL16686899 | 0.80 | NR4A2 (0.58) | NR4A2MAPTGPR84CREBBPPOLB | |
| SCHEMBL8374818 | 0.78 | HSP90AA1 (0.46) | NR4A2MAPTMAPK1HSP90AA1PDE3B | |
| SCHEMBL5365504 | 0.77 | HSP90AA1 (0.53) | MAPTMAPK1HSP90AA1PDE3BPDE3A | |
| SCHEMBL763777 | 0.77 | NR4A2 (0.56) | NR4A2MAPTGPR84CREBBPPOLB | |
| Hydrochloric Acid SCHEMBL6617774 | 0.76 | NR4A2 (0.55) | NR4A2MAPTGPR84CREBBPPOLB | |
| SCHEMBL16687075 | 0.76 | NR4A2 (0.55) | NR4A2MAPTGPR84CREBBPPOLB | |
| SCHEMBL12527041 | 0.76 | PTGER4 (0.52) | TACR1 | |
| SCHEMBL1748606 | 0.76 | PTGER4 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013169-B1 | INDOLE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2012-08-22 | — | — | EP | disclosed |
| EP-2013169-B1 | INDOLE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2012-08-22 | — | — | EP | disclosed |
| US-7968578-B2 | Indole amide derivatives as EP4 receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2011-06-28 | — | — | US | disclosed |
| US-7968578-B2 | Indole amide derivatives as EP4 receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2011-06-28 | — | — | US | disclosed |
| US-7968578-B2 | Indole amide derivatives as EP4 receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2011-06-28 | — | — | US | disclosed |
| US-20090253756-A1 | Indole Amide Derivatives as EP4 Receptor Antagonists | MERCK CANADA INC. (CA) | 2009-10-08 | — | — | US | disclosed |
| US-20090253756-A1 | Indole Amide Derivatives as EP4 Receptor Antagonists | MERCK CANADA INC. (CA) | 2009-10-08 | — | — | US | disclosed |
| US-20090253756-A1 | Indole Amide Derivatives as EP4 Receptor Antagonists | MERCK CANADA INC. (CA) | 2009-10-08 | — | — | US | disclosed |
| EP-2013169-A1 | INDOLE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121578-A1 | INDOLE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253756-A1 | Indole Amide Derivatives as EP4 Receptor Antagonists | PTGER4, PTGER1, PTGER2 | NR4A2 116/4885MAPT 4135/4885MAPK1 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.